(MANE) Veradermics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NYSE (USA) | Market Cap: 4.205m USD | Total Return: 179% in 12m
Industry Rotation: -12.2
Avg Turnover: 55.5M
EPS Trend: 100.0%
Warnings
Negative Equity with losses - insolvent profile
Altman Z'' -1.49 < 1.0 - financial distress zone
Tailwinds
Supp Ema20, Leader, Tailwind, Pullback Swing, Confidence
Veradermics, Incorporated (MANE) is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut. The firm specializes in developing dermatologic and aesthetic therapeutics, with a primary focus on non-hormonal treatments for androgenetic alopecia and alopecia areata. Its lead candidate, VDPHL01, is an oral therapeutic designed for chronic hair loss management in both adult and pediatric populations.
The company’s pipeline also features a dissolvable microarray patch technology, VDMN, targeted at common warts, alongside treatments for molluscum contagiosum and atopic dermatitis. In the biotechnology sector, companies focusing on orphan or underserved dermatological conditions often seek to capture market share through proprietary delivery systems, such as Veradermics’ patch technology, which can improve patient compliance compared to traditional topicals. The aesthetic medicine market remains a high-growth segment of the healthcare industry, driven by increasing consumer demand for non-invasive treatments.
Investors may find additional fundamental insights by reviewing the latest metrics on ValueRay. Given its focus on both medical and aesthetic conditions, Veradermics targets a diverse provider base including dermatologists, pediatricians, and clinical researchers.
- Clinical trial results for VDPHL01 determine entry into the androgenetic alopecia market
- FDA approval timeline for VDMN microarray patch dictates commercialization of wart immunotherapy
- R&D expenditure levels impact cash runway and potential for future equity dilution
- Expansion of the pediatric dermatology pipeline drives long-term valuation and market share
- Strategic partnerships for dissolvable microarray technology influence non-dilutive funding opportunities
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.47 > 0.02 and ΔFCF/TA -7.04 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.47 > 3% & CFO -71.6m > Net Income -70.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 16.66 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (35.1m) vs prev -82.58% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 152.5m - Total Current Liabilities 9.15m) / Total Assets 152.6m |
| B: -0.81 (Retained Earnings -123.4m / Total Assets 152.6m) |
| C: -0.68 (EBIT TTM -71.6m / Avg Total Assets 106.0m) |
| D: -0.45 (Book Value of Equity -123.4m / Total Liabilities 273.6m) |
| Altman-Z'' Score: -1.49 = CCC |
Over the past week, the price has changed by -1.70%, over one month by +42.38%, over three months by +136.73% and over the past year by +178.99%.
| Analysts Target Price | - | - |
Revenue TTM = 0.0 USD
EBIT TTM = -71.6m USD
EBITDA TTM = -71.6m USD
Long Term Debt = 4.00k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 16.0k USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -21.8m USD (calculated as Total Debt 16.0k - CCE 21.8m)
Enterprise Value = 4.18b USD (4.21b + Debt 16.0k - CCE 21.8m)
Interest Coverage Ratio = unknown (Ebit TTM -71.6m / Interest Expense TTM 0.0)
EV/FCF = -58.41x (Enterprise Value 4.18b / FCF TTM -71.6m)
FCF Yield = -1.71% (FCF TTM -71.6m / Enterprise Value 4.18b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 27.41 (Enterprise Value 4.18b / Total Assets 152.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 16.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -56.5m (EBIT -71.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.66 (Total Current Assets 152.5m / Total Current Liabilities 9.15m)
Debt / Equity = -0.00 (negative equity) (Debt 16.0k / totalStockholderEquity, last quarter -121.0m)
Debt / EBITDA = 0.30 (negative EBITDA) (Net Debt -21.8m / EBITDA -71.6m)
Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -21.8m / FCF TTM -71.6m)
Total Stockholder Equity = -121.0m (last fiscal year from totalStockholderEquity)
RoA = -66.03% (Net Income -70.0m / Total Assets 152.6m)
RoE = 57.84% (negative equity) (Net Income TTM -70.0m / Total Stockholder Equity -121.0m)
RoCE = 59.13% (negative capital employed) (EBIT -71.6m / Capital Employed (Equity -121.0m + L.T.Debt 4.00k))
RoIC = -58.80% (negative operating profit) (EBIT -71.6m / (Assets 152.6m - Curr.Liab 9.15m - Cash 21.8m))
WACC = 4.24% (E(4.21b)/V(4.21b) * Re(4.24%) + D(16.0k)/V(4.21b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 4.24% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (yearly) Correlation: -100.0 | Cagr: -82.58%
[DCF] Fair Price = unknown (Cash Flow -71.6m)
EPS Correlation: 100.0 | EPS CAGR: 233.7% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.64 | Chg30d=+14.09% | Revisions=+20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.66 | Chg30d=+7.74% | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=-3.19 | Chg30d=-6.79% | Revisions=-20% | GrowthEPS=+97.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.00 | Chg30d=+9.07% | Revisions=+20% | GrowthEPS=+5.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +20%